Navigation Links
Sanofi-aventis enters into a research and development collaboration with UCSF
Date:1/12/2011

Paris, France - January 12, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the University of California, San Francisco (UCSF) have formed two research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first is an oncology partnership that will focus on project-based collaboration to accelerate research progress through the clinical proof of concept stage. The second collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation.

Sanofi-aventis will be the first industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR). The PBBR program awards funding to projects of potentially high impact and greater creativity, which offer an innovative approach to scientific discovery. The partnership with UCSF enhances sanofi-aventis' approach of setting up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.

Under the terms of the agreement, a UCSF/sanofi-aventis Joint Steering Committee will choose from among UCSF-generated proposals identified for their scientific excellence. Sanofi-aventis will fund up to five grants a year, making additional funds available for student or fellow interns at sanofi-aventis to conduct collaborative research. To further this exchange of ideas, sanofi-aventis will fund an annual research forum bringing together sanofi-aventis and UCSF researchers to share knowledge and perspectives on relevant scientific matters and to review progress of research projects funded through the collaboration.

"As the largest public biomedical research institution in America, UCSF is dedicated to accelerating the translation of leading-edge research into state-of-the-art care for patients," said UCSF Chancellor Susan Desm
'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Page: 1 2

Related biology news :

1. Dana-Farber and sanofi-aventis establish cancer research alliance
2. NINDS awards new Udall Centers for Parkinsons Disease Research
3. Blood-thinning copycat enters malaria fight
4. DFG approves 12 new collaborative research centers
5. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
6. Oxford University Press enters publishing partnership with Infectious Diseases Society of America
7. DFG approves funding for 17 new collaborative research centers
8. Graffinity Enters into Drug Discovery Research Collaboration with Genentech
9. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
10. BIO-key(R) Enters Strategic Partnership With Nlets
11. BIO-key(R) Enters Strategic Partnership With Nlets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... , Saturday to Wednesday, Oct. 18-22, 2014 , ... W. Harbor Drive, San Diego, CA 92101 , ... and other presentations of the latest research in ... plenary session featuring high-scoring abstracts on rare genetic ... various cancers, and treatment for sun sensitivity (Saturday, ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... is available in Spanish . , The ... other forms of synaesthesia in which flavours are evoked ... time units, colours by music, etc. Experts on Experimental ... phenomenon. The results of this research have been published ...
... the ravages the disease can take on almost every ... addictive behaviors, even after a period of peaceable abstinence" ... brain active during decision making. "It,s perhaps ... that they have trouble thinking through a decision," said ...
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
Cached Biology News:1 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 21 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 31 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 4Cognitive, genetic clues identified in imaging study of alcohol addiction 2Cognitive, genetic clues identified in imaging study of alcohol addiction 3Cognitive, genetic clues identified in imaging study of alcohol addiction 4
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, ... report to their offering. The global ... in 2013, and is expected to grow at a ... Molecular biology enzymes, kits, & reagents find applications in ...
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... MD (PRWEB) August 21, 2014 DNA ... making progress in its development of JRC-LAMP-vax, an innovative ... cedar pollen. Phase IC studies began this month in ... to hay fever. , The Japanese red cedar releases ... people in Japan. Mountain Cedar pollen wreaks similar havoc ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... and GAITHERSBURG, Maryland, November 2, 2011 ... -based HPV Testing Increases Screening Coverage and is More ... Online in the Lancet Promising findings published ... a community-based, randomized equivalence trial undertaken by public health authorities ...
... announced that data from REMEDEE ( R andomized ... sirolimus coat ED bio- E ngineered ... Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be ... Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... Credit Suisse Healthcare Conference on Thursday, November 10 at ... (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live ... the Investors page of the Company,s website at ...
Cached Biology Technology:Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 2Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 3Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 5Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 2Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 3
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Biology Products: